Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma

In this nationwide real-world cohort of patients with melanoma receiving prolonged BRAFi/MEKi treatment, a notable proportion of patients who discontinued treatment without progression became long-term survivors. Progression after discontinuation typically occurred within the first year, with BRAFi/MEKi-reinduction being highly effective. Treatment discontinuation could be a viable strategy for selected patients, provided close follow-up and prompt reinitiation upon progression. Identifying clinical or molecular features predictive of sustained tumor control remains essential.